Source: Manufacturing Chemist

IRISYS: Recro announces acquisition of San Diego-based IRISYS

Irisys†capabilities range from formulation development to commercial manufacturing for various dosage forms including oral liquids, sterile injectables, tablets, topicals, liquid/powder filled capsules

Read full article »
Est. Annual Revenue
$5.0-25M
Est. Employees
25-100
Gerald J. Yakatan's photo - Chairman & CEO of IRISYS

Chairman & CEO

Gerald J. Yakatan

CEO Approval Rating

86/100

Read more